After a decade of breakthroughs in biopharma, highlighted by the development of a vaccine against the novel coronavirus in just nine months, expectations of 2022 couldn’t be higher. From a continued focus on oncology and the resurgence of risk appetite in neuroscience, many expect a rebound for the life sciences capital markets paired with a year […]

Cartesian Therapeutics is developing non-permanent cell therapies that can be used soon after diagnosis and address a wide range of diseases beyond cancer. The biotech’s approach to cell engineering relies upon RNA rather than DNA to effect changes within the cells. The benefit, Cartesian President and CEO Murat Kalayoglu, M.D., Ph.D. told BioSpace, is that “our […]

Sutro Biopharma Inc. (NASDAQ: STRO) has announced that it will present preliminary data from its current dose-expansion cohort of the first phase STRO-002 study in ovarian cancer patients at a KPL virtual event. Phase 1 dose expansion group comprises ovarian cancer patients  The first phase dose-expansion cohort comprises advanced ovarian cancer patients with progressing illness who […]